Profile data is unavailable for this security.
About the company
Krka dd Novo Mesto is a Slovenia-based company engaged in the production of pharmaceutical preparations. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services consisting of Spa resorts in Smarjeske Toplice, Dolenjske Toplice, Strunjan, Novo Mesto and Otocec. Krka dd Novo Mesto is a controlling company of the Krka Group that includes two subsidiaries in Slovenia, Terme Krka doo and Farma GRS doo, and over 20 subsidiaries abroad in such countries as Croatia, Germany, Sweden, Poland, Spain, United States, Ireland, among others.
- Revenue in EUR (TTM)2.01bn
- Net income in EUR398.80m
- Incorporated1989
- Employees13.11k
- LocationKrka dd Novo MestoSmarjeska cesta 6NOVO MESTO 8501SloveniaSVN
- Phone+386 73312111
- Fax+386 73321537
- Websitehttps://www.krka.si/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grifols SA | 7.52bn | 372.72m | 6.91bn | 23.83k | 20.62 | 1.48 | 7.67 | 0.9185 | 0.546 | 0.546 | 11.02 | 7.62 | 0.3746 | 1.35 | 7.15 | 315,451.40 | 2.28 | 1.72 | 2.99 | 2.21 | 39.09 | 38.85 | 6.09 | 5.43 | 0.9283 | 2.52 | 0.5621 | -- | 9.41 | 7.18 | 270.81 | -24.15 | -2.07 | -- |
| Sumitomo Pharma Co Ltd | 2.49bn | 605.82m | 6.97bn | 3.83k | 11.49 | 4.38 | 9.62 | 2.79 | 277.11 | 277.11 | 1,141.22 | 727.28 | 0.5438 | 1.95 | 3.99 | 118,318,100.00 | 13.20 | -5.49 | 23.02 | -8.49 | 59.24 | 67.88 | 24.28 | -13.24 | 1.01 | 4.17 | 0.4726 | -- | 26.79 | -3.75 | 107.50 | -10.32 | -0.4856 | -- |
| Krystal Biotech Inc | 328.24m | 172.78m | 7.04bn | 295.00 | 42.08 | 6.89 | 39.64 | 21.45 | 6.84 | 6.84 | 13.00 | 41.78 | 0.3257 | 0.6882 | 3.35 | 1,319,085.00 | 17.14 | 2.46 | 18.75 | 2.63 | 94.08 | -- | 52.64 | 13.06 | 9.56 | -- | 0.00 | 0.00 | 33.94 | -- | 129.74 | -- | -4.24 | -- |
| Kyowa Kirin Co Ltd | 2.73bn | 368.91m | 7.53bn | 5.67k | 20.33 | 1.53 | 14.69 | 2.75 | 128.07 | 128.07 | 949.13 | 1,706.50 | 0.4568 | 1.82 | 2.99 | -- | 6.16 | 6.40 | 7.33 | 7.37 | 74.25 | 74.99 | 13.49 | 14.37 | 2.35 | -- | -- | 46.19 | 0.2559 | 9.31 | 11.98 | 7.35 | 19.80 | 7.10 |
| Axsome Therapeutics Inc | 473.44m | -193.61m | 7.79bn | 683.00 | -- | 125.08 | -- | 16.46 | -4.67 | -4.67 | 11.40 | 1.47 | 0.9121 | 2.40 | 3.50 | 821,761.40 | -37.30 | -59.62 | -68.09 | -80.32 | 91.86 | -- | -40.89 | -134.06 | 1.50 | -28.27 | 0.7255 | -- | 42.53 | -- | -20.05 | -- | 75.71 | -- |
| Mankind Pharma Ltd | 1.29bn | 165.19m | 7.93bn | 27.00k | 48.04 | -- | 31.81 | 6.15 | 42.95 | 43.05 | 334.94 | -- | -- | -- | -- | 5,126,748.00 | -- | 14.93 | -- | 19.39 | 71.39 | 67.59 | 13.00 | 17.70 | -- | 3.64 | -- | 0.00 | 18.98 | 15.79 | 3.90 | 14.03 | 18.41 | -- |
| Halozyme Therapeutics, Inc. | 1.05bn | 502.32m | 7.98bn | 350.00 | 16.92 | 18.77 | 13.97 | 7.61 | 4.76 | 4.76 | 9.90 | 4.29 | 0.5728 | 1.21 | 3.93 | 3,551,006.00 | 27.45 | 22.20 | 35.10 | 25.70 | 84.55 | 80.85 | 47.91 | 45.39 | 1.37 | -- | 0.7499 | 0.00 | 22.44 | 38.95 | 57.71 | -- | 21.50 | -- |
| Eisai Co Ltd | 4.45bn | 235.28m | 8.02bn | 13.51k | 32.97 | 1.59 | 17.42 | 1.80 | 151.67 | 151.67 | 2,866.61 | 3,153.46 | 0.5537 | 0.7996 | 3.33 | 59,839,040.00 | 3.04 | 3.81 | 4.22 | 5.14 | 77.75 | 77.47 | 5.48 | 6.44 | 1.54 | -- | 0.2015 | 98.01 | 6.42 | 2.56 | 9.49 | -17.54 | -14.48 | 0.00 |
| Shanghai Fosun Pharmaceutical (Group) | 4.83bn | 400.79m | 8.07bn | 40.56k | 21.48 | 1.48 | -- | 1.67 | 1.24 | 1.24 | 14.91 | 17.99 | 0.3389 | 2.95 | 4.71 | 975,138.50 | 3.47 | 3.90 | 5.95 | 6.49 | 46.84 | 48.81 | 10.24 | 9.85 | 0.7214 | -- | 0.3806 | 32.08 | -0.8028 | 7.52 | 16.08 | -3.57 | 2.17 | -3.88 |
| Krka dd Novo Mesto | 2.01bn | 398.80m | 8.17bn | 13.11k | 19.12 | 3.32 | 16.60 | 4.06 | 13.02 | 13.02 | 65.60 | 75.06 | 0.6947 | 1.31 | 3.44 | 156,823.60 | 13.79 | 12.80 | 16.67 | 15.31 | 57.71 | 57.39 | 19.85 | 19.11 | 2.57 | -- | 0.0082 | 59.40 | 5.71 | 5.04 | 13.71 | 7.77 | 0.8404 | 14.19 |
| Zydus Lifesciences Ltd | 2.43bn | 459.63m | 8.49bn | 27.92k | 18.47 | -- | 15.03 | 3.50 | 49.08 | 49.08 | 259.31 | -- | -- | -- | -- | 9,345,309.00 | -- | 10.92 | -- | 16.35 | 73.12 | 63.12 | 18.91 | 16.73 | -- | -- | -- | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| Jazz Pharmaceuticals PLC | 3.51bn | -310.83m | 8.61bn | 2.80k | -- | 2.58 | 32.12 | 2.45 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| WuXi XDC Cayman Inc | 621.26m | 162.04m | 8.83bn | 2.27k | 56.25 | 9.29 | 49.59 | 14.21 | 1.16 | 1.16 | 4.43 | 7.00 | 0.5687 | 21.58 | 3.31 | 2,820,164.00 | 14.83 | -- | 19.71 | -- | 33.01 | -- | 26.08 | -- | 2.14 | -- | 0.1225 | -- | 90.80 | -- | 277.24 | -- | -- | -- |
Data as of Feb 18 2026. Currency figures normalised to Krka dd Novo Mesto's reporting currency: Euro EUR
13.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kapitalska druzba ddas of 30 Sep 2025 | 3.49m | 10.65% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 335.26k | 1.02% |
| Schroder Investment Management Ltd.as of 31 Dec 2025 | 169.98k | 0.52% |
| Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 30 Jun 2025 | 124.94k | 0.38% |
| HSBC Global Asset Management (UK) Ltd.as of 30 Nov 2025 | 83.82k | 0.26% |
| InterCapital Asset Management dooas of 31 Dec 2025 | 74.30k | 0.23% |
| NLB Skladi dooas of 31 Dec 2025 | 59.67k | 0.18% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 47.33k | 0.14% |
| Swedbank Robur Fonder ABas of 30 Jan 2026 | 43.20k | 0.13% |
| JPMorgan Asset Management (UK) Ltd.as of 31 Dec 2025 | 27.63k | 0.08% |
More ▼
Data from 30 Jun 2025 - 01 Jan 2026Source: FactSet Research Systems Inc.
